Abstract: Kits for use in treating or preventing an infection caused by a primary bacterium or for use in reducing or preventing overpopulation of the primary bacterium can include a bystander bacterium having a genomically-encoded bacteriotoxin specific for at least the primary bacterium and a first bacteriophage tropic for the bystander bacterium. The bystander bacterium can be provided as a live culture and infection of the bystander bacterium by the first bacteriophage causes expression of the genomically-encoded bacteriotoxin. Methods of treating or preventing an infection caused by a primary bacterium or for reducing or preventing overpopulation of the primary bacterium can include administering a bacteriophage tropic for a bystander bacterium that has a genomically-encoded bacteriotoxin that is expressed upon infection by the first bacteriophage and is specific for at least the primary bacterium.

Abstract: This disclosure relates to sporicidal compositions and uses thereof. The sporicidal compositions include one or more cationic steroidal antimicrobials (CSAs). The sporicidal compositions may be applied to an object to kill or deactivate bacterial spores contacting the sporicidal composition. The object may be a food product, food processing equipment, industrial equipment, or healthcare facility objects. The sporicidal composition may be administered to a subject that has, is suspected to have, or is at risk for an infection associated with spore-forming bacteria.

Abstract: In a general aspect, an apparatus can include a substrate and a post disposed on the substrate. The post can include a plurality of nanotubes and extend substantially vertically from the substrate. The post can have an aspect ratio of a height of the post to a diameter of the post of greater than or equal to 25:1.

Abstract: A system for providing standard mixtures of volatile and semi-volatile organic compounds for simultaneous GC and MS calibration in a calibration vial, wherein calibration mixtures are prepared by diluting calibration analytes in granular PDMS such that most of the analytes are in the PDMS phase and the sample can then be taken from the analytes in the headspace vapor in the calibration vial, wherein a reliable calibration sample can be taken from the calibration vial because the analytes in the PDMS phase and the headspace vapor are in thermodynamic equilibrium, and wherein the method provides solvent-less sampling, long-time stability, ease of use, is quantifiable, and related to temperature.

Abstract: The present disclosure describes compositions and methods for regenerating tissue and/or preventing tissue loss by stimulating stem cells. A method includes providing a treatment composition including one or more CSA compounds and a carrier, applying the treatment composition to a targeted tissue region of a subject, and the treatment composition stimulating tissue regeneration and/or preventing tissue degradation at the targeted region of the subject.

Abstract: A multi-stage stent including a stent body and a bio-erodible material is provided. The stent body can be compressed in an initial state and the bio-erodible material can be coupled to the stent body in a configuration that holds the stent body in an expanded first state, following a first stage expansion from the initial state upon deployment of the stent body. Upon erosion of the bio-erodible material the stent body is released from the first state to expand further in a second stage expansion to a second state.

Abstract: An automated ambient air sampling system and method for monitoring organic compounds that may provide continuous data, the system including a thermal desorption system, an injection port, a pre-concentration system, a gas chromatograph and an ion trap mass spectrometer, wherein an air sampling chamber may also function as a thermal desorption chamber.

Abstract: A method of determining risk factors for Alzheimer's disease in an individual, including assaying a biological medium obtained from the individual for a biomarker selected from Biomarker 1, Biomarker 2, Biomarker 3, or Biomarker 4, where Biomarker 1 has a mass-to-charge ratio (m/z) of 602.3, Biomarker 2 has a m/z of 804.6, Biomarker 3 has a m/z of 874.6, and Biomarker 4 has a m/z of 804.5, and where the presence of the two or more biomarkers in the individual indicates a risk factor of Alzheimer's disease.

Abstract: A microscale device may include a patterned forest of vertically grown and aligned carbon nanotubes defining a carbon nanotube forest with the nanotubes having a height defining a thickness of the forest. The patterned forest may define a patterned frame that defines one or more components of the microscale device. The microscale device may also include a conformal coating of substantially uniform thickness extending throughout the carbon nanotube forest. The carbon nanotube forest may have a thickness of at least three microns. The conformal coating may substantially coat the nanotubes, define coated nanotubes and connect adjacent nanotubes together such that the carbon nanotube forest is sufficiently robust for liquid processing, without substantially filling interstices between individual coated nanotubes. The microscale device may also include a metallic interstitial material infiltrating the carbon nanotube forest and at least partially filling interstices between individual coated nanotubes.

Abstract: A temperature measuring system is disclosed herein. The temperature measuring system includes an optical assembly and a spectral data receiver. The temperature measuring system views passing gas and measures the radiant response of a selected gas. The measurement includes radiant intensities with respect to wavelengths in the infrared region.

Abstract: A computer-implemented method for sharing CAx data includes receiving CAx data in a first CAx format from a first client, storing the CAx data in a plurality of alternate formats, receiving a request for the CAx data from a second client, providing the CAx data to the second client using at least one alternate format of the plurality of alternate formats responsive to receiving the request for the CAx data from the second client. An apparatus and system corresponding to the above method is also disclosed herein.

Abstract: A method of treating a subject having Alzheimer's disease can include assaying a biological medium obtained from the subject for a biomarker selected from the group consisting of Biomarker 1, Biomarker 2, Biomarker 3, Biomarker 4, Biomarker 5, Biomarker 6, Biomarker 7, Biomarker 8, Biomarker 9, Biomarker 10, Biomarker 11, and combinations thereof, where Biomarker 1 has a mass-to-charge ratio (m/z) of 229.13, Biomarker 2 has a m/z of 514.38, Biomarker 3 has a m/z of 602.40, Biomarker 4 has a m/z of 620.42, Biomarker 5 has a m/z of 630.47, Biomarker 6 has a m/z of 703.56, Biomarker 7 has a m/z of 724.52, Biomarker 8 has a m/z of 778.54, Biomarker 9 has a m/z of 799.66, Biomarker 10 has a m/z of 824.60, and Biomarker 11 has a m/z of 842.66. The method can also include relating a characteristic of the biomarker to a presence of Alzheimer's disease in the subject and treating the subject for Alzheimer's disease.

Abstract: A hydrogel polymer includes a ceragenin compound. The ceragenin compound has a hydrophobicity/hydrophilicity that produces a release rate in a range of 0.1-100 ?g/ml for at least 3 days.

Abstract: A method, executed by at least one processor, may include executing a first CAx application configured to enable a first user to edit a first 3D proprietary model comprising a plurality of features for a part that is to be manufactured, wherein the first 3D proprietary model is encoded in a first CAx format. The method may also include, executing a synchronization plugin module for the first CAx application and detecting, with the synchronization plugin module, a request by the first user to generate a first 2D manufacturing drawing and model corresponding to a selected view of the part that is to be manufactured. The method may also include initiating generation of a 2D collaborative model corresponding to the first 2D manufacturing model and initiating storage of the 2D collaborative model on a collaborative data store. A corresponding system and computer readable medium are also disclosed herein.

Abstract: A method for in-situ data acquisition comprises providing a mold, wherein at least a portion of the mold is transparent, inserting a liquid composite molding reinforcement into a cavity of the mold, injecting a fluid into the cavity of the mold, the fluid comprising a fluorescent dye, lighting the mold with an ultraviolet lighting source and capturing a plurality of images of a front portion of the fluid as the fluid advances within the cavity of the mold. Capturing the plurality of images of a front portion of the fluid may include advancing a camera along a camera track as the fluid advances within the cavity of the mold. A corresponding method and computer program product for processing images captured by the above method are also disclosed herein.

Abstract: Disclosed herein are cationic steroidal antimicrobials (“CSAs” or “ceragenins”) and methods of making the same. Particularly advantageous methods are identified for the synthesis of CSAs. CSAs may be formulated for treating subjects with ailments responsive to CSAs, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering CSAs.

Abstract: A system for concurrent CAx workflow includes a collaborative server that manages a model of an engineering object, the model comprising at least design data and analysis data corresponding to the design data, a design client for editing of the design data by a design user, an analysis client for editing of the analysis data by an analysis user concurrent with editing of the design data by the design user; and wherein the collaborative server and the analysis client are collectively configured (i.e., one or both are configured) to enable the analysis user to edit the analysis data, view a plurality of geometric elements within the design data, and create a reference within the analysis data to a selected geometric element of the plurality of geometric elements within the design data. A corresponding apparatus, method, and computer-readable medium are also disclosed herein.

Abstract: The present disclosure as disclosed in various embodiments relates to methods and compositions of treating obesity, inflammation, or obesity-associated metabolic disorders with bacteriophages and processes for preparing the compositions.

Abstract: Techniques of preventing sabotage attacks in cyber-physical systems involve automatically identifying links between nodes of a graph representing cyber-physical systems as vulnerable to sabotage attacks according to a vulnerability metric for each link. The vulnerability metric used depends on the particular sabotage attack used to determine the vulnerable links. Once a computer configured to design cyber-physical systems based on vulnerability to sabotage attacks receives data representing the graph, the computer enumerates the possible links between nodes of the graph along which a sabotage attack may be performed. For each of those links, the computer computes the vulnerability metric. The computer then ranks the links according to respective values of the vulnerability metric. Based on the ranking, a designer may then perform a mitigation analysis that results in changes to the graph to reduce the vulnerability at each node accessible to a malicious actor.

Abstract: Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.